摘要
Coronavirus disease 2019(COviD-19)was first reported three years ago,when a group of individuals were infected with the original SARS-CoV-2 strain,based on which vaccines were developed.Here,we develop six human monoclonal antibodies(mAbs)from two elite convalescents in Wuhan and show that these mAbs recognize diverse epitopes on the receptor binding domain(RBD)and can inhibit the infection of SARS-CoV-2 original strain and variants of concern(VOCs)to varying degrees,including Omicron strains XBB and XBB.
基金
This study was supported by the National Natural Science Foundation of China(32188101 to K.L.,32122008 to Y.W.,32270164 to H.Y.,and 32070160 to H.Y.)
National Science and Technology Major Project(2022YFC2604100 to H.Z.and L.Z.,2021YFC2300702 to L.Z.,and 2021YFF0702004 to Y.C.)
Fundamental Research Funds for the Central Universities(2042023kf0191 and 2042022kf1188 to H.Y.)
Hubei Provincial Natural Science Foundation(2023AFA015 to H.Y.),China Postdoctoral Science Foundation(2023M732705 to Q.L.)
Hubei Provincial Public Health Outstanding Young Talents Project(to K.C.).
